-
Cantor Lifts Aerie's Price Target To $50 Following 'Rock Solid Phase 3 Roclatan Results'
Thursday, September 15, 2016 - 12:11pm | 326Read More...Shares of Aerie Pharmaceuticals Inc (NASDAQ: AERI) soared higher by more than 50 percent Thursday after the company reported Phase 3 data involving Roclatan which met its primary efficacy endpoint. In a report, Dr. Elemer Piros of Cantor Fitzgerald suggested that the data was "impeccable...
